Drug Trial Radar · NCT05073484
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Oct 29, 2021
Primary completion
Mar 30, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
Conditions
- Advanced Solid Tumor
Interventions
BAT6021Drug
Ⅳ infusions
BAT1308Drug
Ⅳ infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: A minimum of 21 days after first dose of BAT6021
- Serious adverse event(SAE)Time frame: From the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Liverpool Hospital
Liverpool, New South Wales, Australia
Macquarie University Hospital
Sydney, New South Wales, Australia
Cabrini Hospital Malvern
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.